Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adrenal function under long-term raloxifene administration.

A R Genazzani1, I Lombardi, G Borgioli

  • 1Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|May 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uterine atony and postpartum haemorrhage: predisposing genetic factors and postmortem findings.

La Clinica terapeutica·2025
Same author

The relevance of inositols treatment for PCOS before and during ART.

European review for medical and pharmacological sciences·2021
Same author

Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery.

Climacteric : the journal of the International Menopause Society·2019
Same author

Oral dehydroepiandrosterone restores ß-endorphin response to OGTT in early and late postmenopause.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2019
Same author

Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.

Journal of endocrinological investigation·2017
Same author

[The putative role and use of DHEA and its association with the hormone replacement therapy].

Minerva ginecologica·2014
Same journal

European society of gynecology (ESG) position paper on the proposed terminology change from PCOS to PMOS.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same journal

Peripheral precocious puberty with unilateral ovarian agenesis in early childhood: a case report and review of literature.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same journal

Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same journal

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same journal

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same journal

Inter-rater reliability and clinical utility of the modified ferriman-gallwey scale in routine practice.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
See all related articles

Long-term raloxifene use in postmenopausal women alters adrenal steroid production, decreasing cortisol and androgens while increasing allopregnanolone. This suggests raloxifene may offer protection against glucocorticoid neurotoxicity and impacts adrenal enzyme activity.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Raloxifene is a selective estrogen receptor modulator used in postmenopausal women.
  • The hypothalamic-pituitary-adrenal (HPA) axis regulates stress response and steroid production.
  • Long-term effects of raloxifene on adrenal function and the HPA axis require further elucidation.

Purpose of the Study:

  • To evaluate the impact of 12-month raloxifene hydrochloride administration on adrenal cortex steroid production.
  • To assess raloxifene's effects on the hypothalamic-pituitary-adrenal axis in postmenopausal women.
  • To investigate raloxifene's influence on hormonal responses to corticotropin-releasing factor (CRF) and adrenocorticotropic hormone (ACTH) stimulation.

Main Methods:

  • 11 postmenopausal women received raloxifene (60 mg/day) for 12 months.

Related Experiment Videos

  • Basal hormonal levels, CRF stimulation tests, and dexamethasone suppression/ACTH stimulation tests were performed.
  • Hormonal assessments included cortisol, dehydroepiandrosterone (DHEA), DHEAS, androstenedione, allopregnanolone, progesterone, estradiol, estrone, ACTH, and beta-endorphin.

    • Main Results:

    • Raloxifene significantly decreased cortisol, DHEA, DHEAS, and androstenedione, while increasing allopregnanolone.
    • Estradiol and estrone levels significantly decreased; ACTH and beta-endorphin levels increased.
    • Adrenal sensitivity to ACTH was reduced, with blunted cortisol response and increased allopregnanolone response.

    Conclusions:

    • Raloxifene alters adrenal steroidogenesis and HPA axis modulation in postmenopausal women.
    • Reduced cortisol levels and response suggest potential neuroprotection against glucocorticoids.
    • Increased allopregnanolone indicates direct effects on adrenal enzymes, potentially offering anxiolytic benefits.